OncoTraj releases a harmonized 813-patient dataset with audited splits for three tasks on osimertinib resistance, showing single-timepoint NGS features yield no model above chance while recovering a TP53 association.
New therapeutic approaches for EGFR-mutated non-small cell lung cancer in the osimertinib era.Cancer Treatment and Research Communications, 44:100945, 2025
1 Pith paper cite this work. Polarity classification is still indexing.
1
Pith paper citing it
fields
cs.LG 1years
2026 1verdicts
UNVERDICTED 1representative citing papers
citing papers explorer
-
OncoTraj: a public benchmark for longitudinal resistance prediction in EGFR-mutant non-small-cell lung cancer on osimertinib
OncoTraj releases a harmonized 813-patient dataset with audited splits for three tasks on osimertinib resistance, showing single-timepoint NGS features yield no model above chance while recovering a TP53 association.